Home » Stocks » CASI

CASI Pharmaceuticals, Inc. (CASI)

Stock Price: $3.39 USD 0.14 (4.31%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.38 -0.01 (-0.30%) Jan 22, 5:12 PM
Market Cap 420.17M
Revenue (ttm) 11.66M
Net Income (ttm) -46.99M
Shares Out 117.94M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.39
Previous Close $3.25
Change ($) 0.14
Change (%) 4.31%
Day's Open 3.18
Day's Range 3.16 - 3.39
Day's Volume 221,501
52-Week Range 1.44 - 3.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 day ago

ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...

PRNewsWire - 2 weeks ago

ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...

PRNewsWire - 4 weeks ago

ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative ther...

PRNewsWire - 2 months ago

ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...

Seeking Alpha - 2 months ago

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of CASI Pharmaceuticals (NASDAQ:CASI) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 40.00% over the past year to ($0.14), which mi...

PRNewsWire - 2 months ago

ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...

Seeking Alpha - 2 months ago

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkp...

Other stocks mentioned: INCY, OCUL, ZLAB
PRNewsWire - 2 months ago

CASI's pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors Collaboration accelerates and expands BioInvent's glo...

PRNewsWire - 3 months ago

ROCKVILLE, Md. and BEIJING, Oct. 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therap...

PRNewsWire - 4 months ago

ROCKVILLE, Md. and BEIJING, Sept.

Seeking Alpha - 5 months ago

CASI Pharmaceuticals, Inc. (CASI) CEO Dr.

Benzinga - 5 months ago

Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

PRNewsWire - 5 months ago

ROCKVILLE, Md. and BEIJING, Aug.

PRNewsWire - 5 months ago

ROCKVILLE, Md. and BEIJING, Aug.

InvestorPlace - 5 months ago

These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on ...

Other stocks mentioned: FDX, FREQ, GES, LEVI
PRNewsWire - 6 months ago

ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.

PRNewsWire - 6 months ago

ROCKVILLE, Md. and BEIJING, July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.

PRNewsWire - 7 months ago

ROCKVILLE, Md. and BEIJING, June 8, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therap...

PRNewsWire - 7 months ago

ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative thera...

Seeking Alpha - 8 months ago

CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy

GuruFocus - 1 year ago

CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share.

GuruFocus - 1 year ago

CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share.

About CASI

CASI Pharmaceuticals, a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute... [Read more...]

Industry
Biotechnology
IPO Date
Jun 11, 1996
CEO
Wei-Wu He
Employees
125
Stock Exchange
NASDAQ
Ticker Symbol
CASI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CASI stock is "Buy." The 12-month stock price forecast is 4.00, which is an increase of 17.99% from the latest price.

Price Target
$4.00
(17.99% upside)
Analyst Consensus: Buy